Genscript Biotech Performance degli utili passati
Criteri Il passato verificati 0/6
Genscript Biotech ha registrato una crescita degli utili a un tasso medio annuo di 18.7%, mentre il settore Life Sciences ha registrato utili in crescita a un tasso medio annuo di 16.9%. I ricavi sono stati in crescita a un tasso medio annuo di 13%.
Informazioni chiave
18.66%
Tasso di crescita degli utili
20.30%
Tasso di crescita dell'EPS
| Life Sciences Crescita del settore | 41.39% |
| Tasso di crescita dei ricavi | 13.02% |
| Rendimento del capitale proprio | -13.43% |
| Margine netto | -55.53% |
| Ultimo aggiornamento sugli utili | 31 Dec 2025 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Jun 23
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Aggiornamento narrativa • Jun 06
1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.Aggiornamento narrativa • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Aggiornamento narrativa • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Aggiornamento narrativa • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Nuova narrativa • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Aggiornamento narrativa • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.Aggiornamento narrativa • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.Aggiornamento narrativa • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Articolo di analisi • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Articolo di analisi • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...Articolo di analisi • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Articolo di analisi • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento narrativa • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Articolo di analisi • Jul 29
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...Articolo di analisi • Jul 24
At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it saw a significant share price rise...Nuova narrativa • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Articolo di analisi • May 14
Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Apr 07
Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Genscript Biotech Corporation ( HKG:1548 ) shares have retraced a considerable 27% in the last month, reversing a fair...Articolo di analisi • Feb 12
Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 27% after a shaky period...Articolo di analisi • Jan 20
Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Genscript Biotech is HK$19.29 based on 2 Stage Free Cash Flow to Equity...Articolo di analisi • Nov 19
Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)
It's not a stretch to say that Genscript Biotech Corporation's ( HKG:1548 ) price-to-sales (or "P/S") ratio of 2.9x...Articolo di analisi • Oct 01
Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Sep 16
What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?
Genscript Biotech Corporation ( HKG:1548 ), might not be a large cap stock, but it received a lot of attention from a...Articolo di analisi • Aug 02
After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar
Genscript Biotech Corporation ( HKG:1548 ) shares have had a really impressive month, gaining 44% after a shaky period...Articolo di analisi • Jun 05
Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Genscript Biotech Corporation ( HKG:1548 ) share price has dived 28% in the...Articolo di analisi • May 10
A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)
Key Insights The projected fair value for Genscript Biotech is HK$14.11 based on 2 Stage Free Cash Flow to Equity With...Articolo di analisi • Apr 13
Is Genscript Biotech (HKG:1548) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Mar 13
Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%
Genscript Biotech Corporation ( HKG:1548 ) shareholders are no doubt pleased to see that the share price has bounced...Articolo di analisi • Jan 26
Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Genscript Biotech Corporation ( HKG:1548 ) shareholders that were waiting for something to happen have been dealt a...Articolo di analisi • Nov 21
Is Genscript Biotech (HKG:1548) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Aug 22
Is Genscript Biotech (HKG:1548) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Genscript Biotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 960 | -533 | 227 | 71 |
| 30 Sep 25 | 894 | -264 | 223 | 66 |
| 30 Jun 25 | 828 | 5 | 220 | 60 |
| 31 Mar 25 | 711 | -31 | 214 | 57 |
| 31 Dec 24 | 594 | -67 | 209 | 54 |
| 30 Jun 24 | 454 | 419 | 101 | -130 |
| 31 Mar 24 | 507 | 421 | 146 | -39 |
| 31 Dec 23 | 560 | 423 | 192 | 53 |
| 30 Sep 23 | 773 | -140 | 383 | 426 |
| 30 Jun 23 | 707 | -185 | 374 | 420 |
| 31 Mar 23 | 667 | -206 | 363 | 405 |
| 31 Dec 22 | 626 | -227 | 352 | 390 |
| 30 Sep 22 | 598 | -315 | 354 | 375 |
| 30 Jun 22 | 570 | -403 | 356 | 361 |
| 31 Mar 22 | 530 | -381 | 330 | 360 |
| 31 Dec 21 | 490 | -359 | 303 | 358 |
| 30 Sep 21 | 483 | -265 | 270 | 341 |
| 30 Jun 21 | 454 | -183 | 235 | 323 |
| 31 Mar 21 | 422 | -194 | 216 | 293 |
| 31 Dec 20 | 391 | -205 | 197 | 263 |
| 30 Sep 20 | 354 | -194 | 171 | 251 |
| 30 Jun 20 | 318 | -183 | 146 | 239 |
| 31 Mar 20 | 296 | -140 | 136 | 212 |
| 31 Dec 19 | 273 | -97 | 126 | 186 |
| 30 Sep 19 | 257 | -59 | 112 | 148 |
| 30 Jun 19 | 241 | -22 | 98 | 109 |
| 31 Mar 19 | 236 | 0 | 89 | 92 |
| 31 Dec 18 | 231 | 21 | 79 | 74 |
| 30 Sep 18 | 216 | 24 | 72 | 58 |
| 30 Jun 18 | 201 | 27 | 65 | 41 |
| 31 Mar 18 | 177 | 26 | 56 | 30 |
| 31 Dec 17 | 153 | 26 | 47 | 18 |
| 30 Sep 17 | 139 | 27 | 48 | 11 |
| 30 Jun 17 | 125 | 28 | 49 | 5 |
| 31 Mar 17 | 120 | 27 | 50 | 2 |
| 31 Dec 16 | 115 | 26 | 51 | 0 |
| 30 Sep 16 | 107 | 26 | 50 | 0 |
| 30 Jun 16 | 99 | 25 | 48 | 0 |
| 31 Mar 16 | 93 | 21 | 47 | 0 |
| 31 Dec 15 | 87 | 18 | 46 | 0 |
| 30 Sep 15 | 82 | 13 | 43 | 0 |
Guadagni di qualità: 1548 al momento non è redditizia.
Margine di profitto in crescita: 1548 al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 1548 non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 18.7% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di 1548 nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: 1548 non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Life Sciences ( 46.3% ).
Rendimento del capitale proprio
ROE elevato: 1548 ha un Return on Equity negativo ( -13.43% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/13 14:21 |
| Prezzo dell'azione a fine giornata | 2026/07/13 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Genscript Biotech Corporation è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |